In the BioHarmony Drug Report Database

"Preview" Icon

Olaparib

Lynparza (olaparib) is a small molecule pharmaceutical. Olaparib was first approved as Lynparza on 2014-12-16. It is used to treat ovarian neoplasms in the USA. It has been approved in Europe to treat ovarian neoplasms. The pharmaceutical is active against poly [ADP-ribose] polymerase 2 and poly [ADP-ribose] polymerase 1. In addition, it is known to target Poly [ADP-ribose] polymerase. Lynparza’s patents are valid until 2031-08-04 (FDA).

 

Trade Name

 

Lynparza
 

Common Name

 

olaparib
 

ChEMBL ID

 

CHEMBL521686
 

Indication

 

ovarian neoplasms
 

Drug Class

 

Poly-ADP-ribose polymerase inhibitors

Image (chem structure or protein)

Olaparib structure rendering